Combination therapy for anthrax using antibiotics and protease inhibitors

Inactive Publication Date: 2007-10-04
AFG BIOSOLUTIONS
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] The invention fulfills this need in the art by providing treatments for anthrax. In one aspect, the invention provides a composition for treating an anthrax infection comprising a therapeutically effective amount of at least one B. anthracis metalloprotease (MP) inhibitor, wherein the MP is other than LF. The MP inhibitor may be a chemical inhibitor, including, but not limiting to, ethylenediamine-tetraacetic acid (EDTA), phosphoramidon, soybean trypsin inhibitor (SBTI), o-phenanthroline, aprotinin, galardin, disulfram, and ebelactone B. The MP inhibitor may also be an antibody raised against a MP. In one embodiment, the antibody is raised against at least one peptide comprising a sequence SEQ ID NO:1, HEFTHYLQGRYEVPGL; SEQ ID NO:2, DVIGHELTHAVTE; SEQ ID NO:3, ADYTRGQGIETY, or a conservative modification of any of these sequences.
[0008] In another aspect, the invention provides a composition for treating an anthrax infection comprising a therapeutically effectiv

Problems solved by technology

Thus, if used as a biological weapon, B. anthracis is expected to cause massive casualties and high mortality

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy for anthrax using antibiotics and protease inhibitors
  • Combination therapy for anthrax using antibiotics and protease inhibitors
  • Combination therapy for anthrax using antibiotics and protease inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 1

Materials and Methods

[0050] Microbial strains. The non-encapsulated Bacillus anthracis strain 34F2 (Sterne) [pXO1+, pXO2−] obtained from the Colorado Serum Company (Boulder, Colo.) was used in animal challenge experiments. The 50% lethal doses (LD50s) by the inraperitoneal (i.p.) route were established earlier (Popov et al., 2004) and the LD50 value for intraperitoneal challenge for DBA2 mice was found to be 3×106 spores per mouse. The non-encapsulated, atoxigenic strain of B. anthracis (delta Ames) [pXO1−, pXO2−] was provided by Dr. J. Shiloach (National Institutes of Health, Bethesda, Md.). B. cereus strain ATCC #11778 and B. subtilis strain #23857 were purchased from American Type Culture Collection (Manassas, Va.).

[0051] Mice. Female DBA2 mice (9 weeks old) were obtained from Taconic (Germantown, N.Y.) and were used in all experiments described in the examples that follow.

[0052] Reagents. The following substances were used: ciprofloxacin (ICN Biomedicals, lot no. 4913F), pho...

example 2

Genomic Analysis of B. Anthracis Secreted Proteins as Potential Virulence Factors

[0061] In order to evaluate the pathogenic effect of B. anthracis proteins other than the known lethal and edema toxins, a nontoxigenic and nonencapsulated strain of B. anthracis, delta Ames, was analyzed. The delta Ames strain lacks both plasmids, pXO1 and pXO2.

[0062] First, an analysis of the chromosome sequence of the B. anthracis Ames strain was performed based on shared sequence homology with pathogenic factors in other bacterial species. (Supran et al., 2002; Read et al., 2003) This analysis revealed a variety of potential virulence-enhancing factors, including collagenases, phospholipases, haemolysins, proteases, and other enterotoxins. In fact, the B. cereus group of bacteria, which are pathogenic to humans or insects and includes B. anthracis, B. thuringiensis, and B. cereus, has more sequences that are predicted to be secreted proteins than does nonpathogenic B. subtilis (Read et al., 2003)...

example 3

Hemorrhagic and Collagenolytic Activities of Anthrax Proteases

[0066] The proteins secreted by three Bacillus species (B. anthracis, B. cereus, and B. subtilis) into culture media were prepared by successively inoculating culture media with spores and incubating them overnight at 37° C. The bacterial cells were removed by centrifugation and the supernatant was sterilized by filtering through a 0.22μ filter. The supernatant was then concentrated 50-fold using an ultrafiltration device, such as an Amicon Ultra 15 filter (Millipore, MA) with a 10 KDa cutoff size. SDS-PAGE gel separation of culture supernatant (“BACS”) (FIG. 1A) demonstrates its protein content. Similar procedures were used to prepare culture supernatants for B. cereus (“BCCS”), ATCC #11778, and B. subtilis (“BSCS”), ATCC #23857.

[0067] Gelatinase and collagenase activity of BACS is readily detected by zymography using collagen type I or gelatin (denatured collagen) (FIGS. 1D and 1E). A major band of gelatinase activit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Digital informationaaaaaaaaaa
Timeaaaaaaaaaa
Login to view more

Abstract

The invention provides compositions for treatment anthrax infection. The composition comprises a therapeutically effective amount of at least one B. anthracis metalloprotease inhibitor. The composition may further include an antimicrobial agent. The invention also provides methods for treating anthrax infection in a human or an animal subject. The method comprises administering to the subject a therapeutically effective amount of a composition of the present invention.

Description

[0001] This application is a continuation-in-part of the U.S. patent application Ser. No. 11 / 041,881, filed Jan. 25, 2005, which claims priority under 35 U.S.C. § 119(e) to U.S. provisional application No. 60 / 612,616, filed Sep. 24, 2004, U.S. provisional application No. 60 / 615,591, filed Oct. 5, 2004, and U.S. Provisional application No. 60 / 622,112, filed Oct. 27, 2004, all of which are incorporated herein by reference. This application also claims the benefit of U.S. provisional application No. 60 / 612,616, filed Sep. 24, 2004 and U.S. provisional application No. 60 / 615,591, filed Oct. 5, 2004.[0002] This invention was made with partial Government support under contract numbers W9111NF-04-C-0046 and MDA972-02-C-0067 awarded by Defense Advanced Research Project Agency (DARPA). The Government has certain rights in the invention.BACKGROUND OF THE INVENTION [0003] This invention relates to compositions and methods of treating anthrax. [0004] Anthrax is a severe, often fatal disease cau...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/40A61K31/195A61K31/473A61K36/48A61K31/366
CPCA61K31/7056A61K38/212A61K38/215A61K38/217A61K39/00A61K2300/00A61K31/145A61K31/198A61K31/365A61K31/405A61K31/4375A61K31/496A61K31/65A61K45/06Y02A90/10
Inventor ALIBEK, KENPOPOVA, TAISSIAPOPOV, SERGUEIHOPKINS, SVETLANA
Owner AFG BIOSOLUTIONS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap